A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations.
Ludivine Grzelak, Sarah Temmam, Cyril Planchais...
https://pubmed.ncbi.nlm.nih.gov/32817357Actively Recruiting
Phase Not Applicable
Age: 18Years +
All Genders
ID07085611
Study of the Neutralizing Power of Serum Antibodies - 2 (PNAS-2)
Led by Centre Hospitalier Régional d'Orléans · Updated on 2025-12-19
30
Participants Needed
1
Research Sites
254 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to measure and describe how the body's antibody response changes over time after receiving vaccines or monoclonal antibody treatments for COVID-19 and Monkeypox. It focuses on people who may be at higher risk due to weakened immune systems or other health conditions. The study evaluates the strength of neutralizing antibodies in the blood and nasal passages as a sign of protection against these infections. Participants receive standard vaccines or monoclonal antibody treatments for SARS-CoV-2 and/or Monkeypox as part of their usual care. The study itself does not provide these treatments but collects blood and optional nasal samples at each visit to analyze antibody activity. Samples are tested using validated methods to assess neutralizing power against both viruses. Each participant is followed for up to 60 months, during which blood and nasal samples are collected multiple times to track changes in antibody levels. Researchers will study the evolution of serum and mucosal antibody responses over this period. The study monitors how long protection lasts and collects detailed laboratory results related to immune response while participants continue their routine health care.
CONDITIONS
Brief Title
Neutralizing Power of Serum Antibodies - 2
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
- Adults (≥18 years)
- Patients receiving or scheduled to receive anti-SARS-CoV-2 and/or anti-MPXV vaccines or monoclonal antibodies
- Patients have provided written informed consent
You will not qualify if you...
- Persons under guardianship or curatorship
- Persons under legal protection
- Persons deprived of liberty
- Persons not affiliated to a social security scheme
- Pregnant or breastfeeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Sample Collection
Duration - Up to 60 months
Participants provide venous blood samples and optional nasal swabs at each visit to measure and describe the evolution of the humoral immune response to SARS-CoV-2 and MPXV.
Multiple visits over 60 months for sample collection
Trial Site Locations
Total: 1 location
1
CHU Orléans
Orléans, France, 45067
Actively Recruiting
Loading map...
Research Team
T
Thierry PRAZUCK, Dr
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies.
Delphine Planas, Timothée Bruel, Ludivine Grzelak...
https://pubmed.ncbi.nlm.nih.gov/33772244Complement-dependent mpox-virus-neutralizing antibodies in infected and vaccinated individuals.
Mathieu Hubert, Florence Guivel-Benhassine, Timothée Bruel...
https://pubmed.ncbi.nlm.nih.gov/37196656